Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Gross Margin (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Gross Margin for 9 consecutive years, with 69.35% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin fell 709.0% year-over-year to 69.35%, compared with a TTM value of 74.53% through Dec 2025, up 248.0%, and an annual FY2025 reading of 74.53%, up 248.0% over the prior year.
  • Gross Margin was 69.35% for Q4 2025 at Puma Biotechnology, down from 77.65% in the prior quarter.
  • Across five years, Gross Margin topped out at 80.79% in Q4 2022 and bottomed at 63.87% in Q3 2024.
  • Average Gross Margin over 5 years is 75.18%, with a median of 76.49% recorded in 2024.
  • The sharpest move saw Gross Margin crashed -1449bps in 2023, then surged 1378bps in 2025.
  • Year by year, Gross Margin stood at 78.51% in 2021, then increased by 3bps to 80.79% in 2022, then fell by -18bps to 66.3% in 2023, then rose by 15bps to 76.44% in 2024, then decreased by -9bps to 69.35% in 2025.
  • Business Quant data shows Gross Margin for PBYI at 69.35% in Q4 2025, 77.65% in Q3 2025, and 76.54% in Q2 2025.